{"log_id": 7936415797231853679, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.000734, "average": 0.991379, "min": 0.833193}, "location": {"width": 763, "top": 197, "height": 64, "left": 191}, "words": "在三项针对慢性便秘患者的多中心、随机、双盲、12周的安慰剂对照研究中证实了本"}, {"probability": {"variance": 0.000465, "average": 0.989882, "min": 0.859105}, "location": {"width": 802, "top": 243, "height": 67, "left": 153}, "words": "品的有效性(服用普芦卡必利的患者共1279例,其中女性1124例,男性155例)。每项研"}, {"probability": {"variance": 0.004976, "average": 0.985898, "min": 0.54025}, "location": {"width": 802, "top": 290, "height": 66, "left": 156}, "words": "究中普芦卡必利剂量都包括每日2mg和4mg。研究中慢性便秘的定义为:每周完全自发排"}, {"probability": {"variance": 0.000633, "average": 0.990208, "min": 0.862459}, "location": {"width": 804, "top": 338, "height": 65, "left": 155}, "words": "便(SCBM)次数≤2次,此外在就诊前下列一项或多项症状出现至少6个月:至少四分之一的"}, {"probability": {"variance": 8.5e-05, "average": 0.995831, "min": 0.952929}, "location": {"width": 796, "top": 384, "height": 66, "left": 156}, "words": "排便硬或非常硬,至少四分之一的时间有排便不完全感,或至少四分之一的时间排便用力"}, {"probability": {"variance": 0.004254, "average": 0.979149, "min": 0.703548}, "location": {"width": 791, "top": 430, "height": 66, "left": 158}, "words": "实际参加研究的患者平均有20年的便秘史,研究中导入期平均每周完全自发排便(SCBM)"}, {"probability": {"variance": 7.1e-05, "average": 0.996063, "min": 0.955749}, "location": {"width": 800, "top": 477, "height": 65, "left": 164}, "words": "≤0.5次。主要有效性终点是排便正常的受试者比例,定义为在12周治疗期内平均每周完"}, {"probability": {"variance": 0.000162, "average": 0.99319, "min": 0.94491}, "location": {"width": 804, "top": 523, "height": 67, "left": 162}, "words": "全自发排便(SCBM)次数≥3次。在这三项研究中,两种剂量的主要终点在统计学上均优"}, {"probability": {"variance": 0.005747, "average": 0.973142, "min": 0.573818}, "location": {"width": 803, "top": 571, "height": 62, "left": 164}, "words": "于安慰剂(p<0.001)。4mg并不比2mg的疗效有所增加。服用2mg的患者平均每周完全自"}, {"probability": {"variance": 0.001631, "average": 0.987278, "min": 0.736972}, "location": {"width": 802, "top": 616, "height": 64, "left": 165}, "words": "发排便次数≥3次的比例是27.8%(第4周)和23.6%(第12周),安慰剂组为10.5%(第"}, {"probability": {"variance": 0.003524, "average": 0.977713, "min": 0.750452}, "location": {"width": 768, "top": 662, "height": 63, "left": 184}, "words": "周)和11.%(第12周)。对于每周完全自发排便次数增加≥1次这一最关键的次要终点"}, {"probability": {"variance": 0.002232, "average": 0.981632, "min": 0.789832}, "location": {"width": 807, "top": 708, "height": 65, "left": 168}, "words": "2mg组有48.1%(第4周)和43.1%(第12周)的患者可以达到,安慰剂组有23.4%(第4"}, {"probability": {"variance": 3.5e-05, "average": 0.995809, "min": 0.974964}, "location": {"width": 376, "top": 773, "height": 45, "left": 170}, "words": "周)和246%(第12周)的患者可以达到"}, {"probability": {"variance": 2e-05, "average": 0.997897, "min": 0.973592}, "location": {"width": 762, "top": 800, "height": 61, "left": 213}, "words": "对这三项研究在第4周和第12周进行评价时发现,在包括腹部症状、粪便及直肠症状"}, {"probability": {"variance": 4.6e-05, "average": 0.997193, "min": 0.96396}, "location": {"width": 787, "top": 846, "height": 62, "left": 174}, "words": "等一组有效的疾病特异性的症状在内的量表评分上均有显著改善。在第4周及第12周时,"}, {"probability": {"variance": 1e-05, "average": 0.99782, "min": 0.988028}, "location": {"width": 804, "top": 891, "height": 62, "left": 175}, "words": "生活质量量表上的很多项目也有很大改善,如对治疗及排便习惯的满意程度、生理和心理的"}, {"probability": {"variance": 0.000332, "average": 0.991874, "min": 0.943728}, "location": {"width": 167, "top": 965, "height": 35, "left": 178}, "words": "不适、焦虑和担忧"}, {"probability": {"variance": 2e-06, "average": 0.998679, "min": 0.993263}, "location": {"width": 432, "top": 996, "height": 49, "left": 219}, "words": "服用本品不会发生反跳现象,也不会产生依赖性"}, {"probability": {"variance": 0.000337, "average": 0.994326, "min": 0.889929}, "location": {"width": 743, "top": 1030, "height": 61, "left": 220}, "words": "进行了一项全面的QT间期的研究以评价本品治疗剂量(2mg)和超治疗剂量(10m"}, {"probability": {"variance": 2.1e-05, "average": 0.997492, "min": 0.977441}, "location": {"width": 805, "top": 1074, "height": 64, "left": 181}, "words": "对QT间期的影响,并与安慰剂及一种阳性对照药进行比较。研究结果显示,在两种剂量水"}, {"probability": {"variance": 4.3e-05, "average": 0.996486, "min": 0.973066}, "location": {"width": 802, "top": 1122, "height": 60, "left": 185}, "words": "平上,本品和安慰剂之间的平均QT测量结果和异常值均无显著性差异。也进一步证实了两"}, {"probability": {"variance": 0.000209, "average": 0.991969, "min": 0.937377}, "location": {"width": 803, "top": 1166, "height": 63, "left": 185}, "words": "项安慰剂对照的QT间期研究结果。在双盲临床研究中,QT相关不良事件及室性心律失常"}, {"probability": {"variance": 1.9e-05, "average": 0.996573, "min": 0.985893}, "location": {"width": 290, "top": 1235, "height": 39, "left": 186}, "words": "的发生率低,且与安慰剂组相当"}, {"probability": {"variance": 0.006021, "average": 0.970909, "min": 0.610374}, "location": {"width": 764, "top": 1254, "height": 69, "left": 228}, "words": "长达2.6年开放研究提供了长期使用本品的安全性和有效性的数目前尚无治疗持"}, {"probability": {"variance": 2.9e-05, "average": 0.995795, "min": 0.977337}, "location": {"width": 397, "top": 1321, "height": 49, "left": 192}, "words": "续时间超过12周的安慰剂对照的有效性数据"}, {"probability": {"variance": 0, "average": 0.783183, "min": 0.783183}, "location": {"width": 27, "top": 1339, "height": 23, "left": 909}, "words": "心"}, {"probability": {"variance": 1.7e-05, "average": 0.996517, "min": 0.987826}, "location": {"width": 117, "top": 1425, "height": 33, "left": 200}, "words": "【药理毒理】"}, {"probability": {"variance": 0, "average": 0.996101, "min": 0.996101}, "location": {"width": 137, "top": 1389, "height": 56, "left": 941}, "words": "约"}, {"probability": {"variance": 1e-06, "average": 0.9985, "min": 0.997369}, "location": {"width": 85, "top": 1474, "height": 28, "left": 198}, "words": "药理作用"}, {"probability": {"variance": 0, "average": 0.892884, "min": 0.892884}, "location": {"width": 212, "top": 1439, "height": 81, "left": 909}, "words": "★"}, {"probability": {"variance": 0.018975, "average": 0.917562, "min": 0.678988}, "location": {"width": 109, "top": 1636, "height": 40, "left": 1090}, "words": "仪供存档"}], "language": 3}